IPO
Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering.
MorphoSys AG announced today that its shares will be included in the MDAX as of September 24, 2018 as announced by Deutsche Börse.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation therapies for back of the eye disease
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
Medigene AG announces that the Medigene share will be part of the SDAX from 24 September 2018 onwards, following the restructuring of the Deutsche Börse indices.
Cellmid Limited today advised that the Share Purchase Plan (“SPP”) announced on 31 July 2018 with an offer price of $0.38 has now closed.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Only a month after raising $85.4 million in a Series E financing, Sutro Biopharma filed for an initial public offering (IPO). The company plans to raise $75 million with the IPO.
In April, Alzheon attempted an initial public offering (IPO) to raise $80 million, but withdrew the offering. It has decided to try again, filing with the U.S. Securities and Exchange Commission (SEC), indicating it planned to raise $40 million in an IPO.
PRESS RELEASES